Ingredient or product comparison
Injection vs Topical — Penetration Depth Matches Your Baseline Skin Thickness
GHK-Cu can be administered subcutaneously (injected into the hypodermis) or topically (applied to the stratum corneum in a penetration-enhancing vehicle). The decision isn't about convenience. It's about where the peptide needs to act and whether your skin arc
This source-based comparison does not add ratings or recommend a winner.
- GHK-Cu can be administered subcutaneously (injected into the hypodermis) or topically (applied to the stratum corneum in a penetration-enhancing vehicle). The decision isn't about convenience. It's about where the peptide needs to act and whether your skin architecture allows transdermal delivery to reach that depth. In your 30s, dermal thickness averages 1.2–1.5mm on facial skin, compared to 0.9–1.1mm in individuals over 50. That extra 0.3–0.4mm of intact dermis creates a penetration barrier that limits how much topical GHK-Cu actually reaches fibroblast-dense layers.
- A 2021 study using radiolabeled copper peptides found that topical application at 2% concentration delivered approximately 8–12% of the applied dose to the papillary dermis. The uppermost dermal layer where fibroblasts reside. Subcutaneous injection, by contrast, deposits the peptide directly into the reticular dermis and hypodermis, bypassing the epidermal barrier entirely. For individuals in their 30s with thicker, less compromised skin, subcutaneous administration is the more reliable route if the goal is systemic collagen signaling. Topical delivery works better once the epidermal barrier has thinned. Which typically happens after age 45.
- Dose equivalence isn't linear. A 1mg subcutaneous injection delivers roughly the same fibroblast-available GHK-Cu as a 10–12mg topical application, assuming a penetration rate of 8–10%. If you're using topical formulations, you need higher concentrations to compensate for barrier loss. But that also increases the risk of localized copper accumulation in the epidermis, which can trigger reactive oxygen species formation and paradoxically accelerate aging. Our team recommends subcutaneous administration at 0.5–1.0mg per session, 2–3 times weekly, for individuals in their 30s. Topical application is reserved for spot treatment of early photoaged areas. Not full-face protocols.